30 closest matches · ranked by relevance
Myeloid Leukemia, Chronic, Accelerated Phase · Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Primary: Percent of Participants With Major Hematologic Response (MaHR) With 6 Months of Follow-up From Date of Last Enrollment - Randomized Population — 48.0; 47.9 percentage of…
Leukemia
Primary: Number of Participants Who Died, Experienced Other Serious Adverse Events (SAEs), Adverse Events (AEs) and AEs Leading to Study Drug Discontinuation. — 3; 2; 1; 1…
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative · Chronic Neutrophilic Leukemia
Primary: Percentage of First 25 Enrolled Patients With a Hematologic Response to Ruxolitinib (Complete Response (CR), Partial Response (PR)) — 32; 4 percentage of participants…
Myeloid Leukemia, Chronic, Chronic-Phase
Primary: Percent of Participants With Major Cytogenetic Response (MCyR) at 6 Months Follow-Up — 51.8; 49.0 percentage of Participants
CML in Chronic Phase
Primary: Percentage of Participants With Molecular Response (MR4^0) at 18 Months — 38.3 Percentage of Participants
Chronic Myelogenous Leukemia in Chronic Phase
Primary: Number of Participants With Confirmed Complete Molecular Response (CMR) — 34 Participants
Chronic Myelogenous Leukemia · Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive) · Hypereosinophilic Syndrome
Primary: Number of Participants With Major Cytogenetic Response (MCyR) — 191; 44; 22 Participants
Chronic Myelogenous Leukemia - Chronic Phase
Primary: Number of Participants With Adverse Events and Serious Adverse Events for Cohorts A and B up to 24 Weeks — 23; 26; 1; 3 Participants
Chronic Myeloid Leukemia
Primary: Percentage of Leukemic Stem Cells Present in Bone Marrow Aspirate Samples, in This Patient Population — 37.4; 2.32; 0.7; 7.04 percentage of leukemic stem cells
Chronic Myelogenous Leukemia
Primary: Percentage of Participants Who Achieved Major Molecular Response (MMR) During the First 12 Months — 74 Participants
Chronic Myeloid Leukemia · Blast Crisis
Primary: Major and Overall Hematologic Response (MaHR and OHR) — 2; 34; 36; 4 Participants
Chronic Myeloid Leukemia · Ph+ Acute Lymphoblastic Leukemia
Primary: Percentage of CP-CML Participants With Major Cytogenetic Response (MCyR) — 50.7; 70.3 percentage of participants
Chronic Myelogenous Leukemia
Primary: Kaplan-Meier Estimates of Overall Survival (All Randomized Participants) — 98.9; 97.7; 96.0; 93.6 Percentage of participants
Leukemia, Myelogenous, Chronic
Primary: Participants With Complete Molecular Response (Molecular CR) — 23 Participants
Philadelphia Chromosome Positive · Chronic Myelogenous Leukemia in Chronic Phase
Primary: MMR Rate at 12 Mos. of Nilotinib Treatment on Study in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Who…
Accelerated Phase Chronic Myelogenous Leukemia · Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative · Blastic Phase Chronic Myelogenous Leukemia
Primary: Response Rate Including Complete Response, Partial Response, and Hematological Improvement Assessed by Blood Cell Counts, Number of Blasts in Bone Marrow, and Clinical…
Chronic Myeloid Leukemia · Philadelphia-Positive Myeloid Leukemia
Primary: Number of Participants With Major Cytogenetic Response (MCyR) at Week 12 — 36; 14 Participants
Chronic Myeloid Leukemia
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 0; 1 participants
Myelogenous Leukemia, Chronic
Primary: Major Molecular Response Rate (MMR) at 12 Months Between All 3 Arms - With Imputation — 22.3; 44.3; 42.7 Percentage of participants — p=<0.0001
Myeloproliferative Neoplasms
Primary: Number of Participants With Hematological Response, as Measured by Any One or More of the Following Response Assessments: IWG-MDS and IWG-MF Criteria as Accurate and…
Leukemia · Chronic Myelogenous Leukemia · Chronic Myeloid Leukemia
Primary: Number of Participants With Complete Response — 3 Participants
Chronic Myelogenous Leukemia
Primary: Number of Participants With Major Molecular Response (MMR) Rate at 24 Weeks — 40; 10 Participants — p=0.029
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Primary: Number of Participants With a Platelet Response — 12; 0 Participants
Chronic Myelogenous Leukemia
Primary: Major and Overall Hematologic Response (MaHR and OHR) — 9; 103; 112; 12 participants
Chronic Phase Chronic Myeloid Leukemia
Primary: The Number of Imatinib-related Adverse Events (AEs) That Were Resolved, Improved, Remained Unchanged, or Worsened After 3 Months of Dasatinib Treatment — 91; 2; 27; 1…
Leukemia · Chronic Myelogenous Leukemia
Primary: Number of Participants With Molecular Complete Remission at 3 Month Post Transplant — 3 participants
Myeloid Leukemia, Chronic
Primary: Cytogenetic Response in Imatinib-Intolerant and Imatinib-Resistant Participants at Week 24 — 45; 29; 75; 92 percentage of participants
Leukemia
Primary: Percentage of Chronic Phase Chronic Myeloid Leukemia (CP - CML) Participants With Major Cytogenetic Response (MCyR) — 50.8 Percentage of participants
Chronic Myeloid Leukemia
Primary: Percentage of Participants With Complete Cytogenetic Response (CCyR) at Year 1 — 70.0; 68.3 Percentage of Participants — p=0.667
Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia
Primary: Rate of Major Molecular Response (MMR) at 6 Cycles for Ph+ CML CP Patients Resistant or Intolerant to Imatinib or Dasatinib — 39.4 Percentage of participants